Literature DB >> 15749662

Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities.

Ulrike Hartmann1, Tim H Brümmendorf, Stefan Balabanov, Christian Thiede, Thomas Illme, Markus Schaich.   

Abstract

BACKGROUND AND OBJECTIVES: Acute myeloid leukemia (AML) is a malignant, genetically heterogenous disorder characterized by uncontrolled growth of immature myeloid cells. The aim of this study was to analyze whether telomere length and/or hTERT expression are correlated with clonal chromosomal aberrations in AML. DESIGN AND METHODS: Telomere length in mononuclear cells derived from 137 previously untreated patients with >or= 80% blasts was analyzed by flow fluorescent in situ hybridization. Results were expressed in telomere fluorescence Units (1 TFU=1 kb). The expression of hTERT, including its different splice variants was studied by reverse transcription-polymerase chain reaction.
RESULTS: Age-adjusted telomere length in AML patients was significantly reduced as compared to in matched controls, consisting of peripheral blood granulocytes from healthy individuals (0-90 years) (median: -2.5 TFU; p<0.001). Patients with an aberrant karyotype had significantly shorter telomeres than patients with a normal karyotype (median -3.0 vs. -2.3 TFU; p=0.03). The shortest telomeres were found in patients with multiple aberrations (median -3.7 TFU; p=0.03). hTERT expression was found to be correlated with chromosomal abnormalities as well as with the detection of functional hTERT splicing variants. INTERPRETATION AND
CONCLUSIONS: These findings suggest an important role of intense telomere loss in the development of genetic instability during the pathogenesis of AML. It is assumed that critical telomere shortening in AML blasts could lead to telomerase activation and therefore prevent blasts from replicative senescence, one possible mechanism for clonal selection and disease progression. Therefore, telomere length might serve as a prognostic marker for AML patients. These findings would have to be confirmed in large, prospective studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749662

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  19 in total

1.  A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.

Authors:  Jooeun Bae; Weihua Song; Robert Smith; John Daley; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi
Journal:  Br J Haematol       Date:  2012-04-26       Impact factor: 6.998

Review 2.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

Review 3.  Maintenance of telomere length in AML.

Authors:  Peter M Lansdorp
Journal:  Blood Adv       Date:  2017-11-28

Review 4.  Biological and clinical implications of telomere dysfunction in myeloid malignancies.

Authors:  Ashwin Kishtagari; Justin Watts
Journal:  Ther Adv Hematol       Date:  2017-10-06

5.  Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.

Authors:  Youjin Wang; Tao Wang; Casey Dagnall; Michael Haagenson; Stephen R Spellman; Belynda Hicks; Kristine Jones; Stephanie J Lee; Sharon A Savage; Shahinaz M Gadalla
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-04       Impact factor: 5.742

Review 6.  Vaccines as consolidation therapy for myeloid leukemia.

Authors:  Gheath Alatrash; Jeffrey J Molldrem
Journal:  Expert Rev Hematol       Date:  2011-02       Impact factor: 2.929

7.  Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia.

Authors:  A M Aalbers; R T Calado; N S Young; C M Zwaan; C Wu; S Kajigaya; E A Coenen; A Baruchel; K Geleijns; V de Haas; G J L Kaspers; T W Kuijpers; D Reinhardt; J Trka; M Zimmermann; R Pieters; V H J van der Velden; M M van den Heuvel-Eibrink
Journal:  Leukemia       Date:  2013-02-21       Impact factor: 11.528

Review 8.  The role of telomere biology in bone marrow failure and other disorders.

Authors:  Sharon A Savage; Blanche P Alter
Journal:  Mech Ageing Dev       Date:  2007-11-19       Impact factor: 5.432

Review 9.  T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.

Authors:  Naval Daver; Ahmad S Alotaibi; Veit Bücklein; Marion Subklewe
Journal:  Leukemia       Date:  2021-05-05       Impact factor: 11.528

Review 10.  Chromosomal Instability in Acute Myeloid Leukemia.

Authors:  Mateus de Oliveira Lisboa; Paulo Roberto Slud Brofman; Ana Teresa Schmid-Braz; Aline Rangel-Pozzo; Sabine Mai
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.